Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A Multi-Country Non-Interventional Prospective Cohort Study Among Patients with Human Growth Hormone (hGH) Treatments Under Routine Clinical Care

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Growth Delay
  • Age: Between 0 Year(s) - 17 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Prescription of Genotropin daily hGH for Growth Hormone Deficiency (GHD) or prescription of other daily hGH treatments for GHD.
    2. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed and agree to all pertinent aspects of the study. Assent will also be sought from children of applicable age in line with national guidance. In all cases, the treating physician responsible for enrolling the patient into the registry will assess the appropriateness of gaining assent from a patient (or a legally acceptable representative) at their discretion during routine clinical care.

You may not be eligible for this study if the following are true:

    1. Participation in any interventional clinical trials at the time of enrollment.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.